Clinical Trials Logo
  1. Home
  2. T-lymphoblastic Lymphoma
  3. NCT03558412

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

T-lymphoblastic Lymphoma Clinical Trial

Official title:
A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma

Clinical Trial Summary

To explore the safety, tolerability, and clinical effects of decitabine combined with Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic lymphoma.

Clinical Trial Description

This is a prospective, open，investigator initial clinical trial with a single arm, aimed to evaluate the safety, tolerability, and efficacy of decitabine combined with Second-line chemotherapy regimens (CODOX-M/IVAC) in relapsed or refractory T-lymphoblastic lymphoma. A total of 40 patients are planned to be enrolled into the study. Patients with diagnosis of relapsed or refractory T-lymphoblastic lymphoma will be treated with decitabine plus CODOX-M/IVAC. The primary end point is responder rate (RR) and time to progression (TTP), and the secondary end points include overall survival (OS) and the median survival time (MST). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03558412
Study type Interventional
Source Zhengzhou University
Contact Mingzhi zhang, Pro,Dr
Phone 13838565629
Email Mingzhi_zhang@126.com
Status Recruiting
Phase Phase 4
Start date June 1, 2018
Completion date June 1, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1
Not yet recruiting NCT05068401 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Withdrawn NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04004637 - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia Phase 1
Recruiting NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study Phase 1
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2